Science Explorer Back to mapMap
Discussion
Company · Berlin · Germany

Noxxon Pharma (Germany)

noxxon.comROR OpenAlex
Research works
84
▼ 91% vs 2018-21
Citations
3.9k
46.5 per fractional work
Top-10% rate
3.1%
all institutions 10.0%
Open access
43%
world 40%
International
34%
world 18%
Noxxon Pharma (Germany)

Not ranked overall: Noxxon Pharma (Germany) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Noxxon Pharma (Germany) work in?

In all years, 58% of research at Noxxon Pharma (Germany) is in Life Sciences, 33% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (47%), Medicine (32%), Immunology and Microbiology (7%). It does 3.3× the world's share of Life Sciences.

Life Sciences: 49 fractional works · 58.4% of its workBiochemistry, Genetics and Molecular Biology: 40 fractional works · 47.0% of its workMolecular Biology: 36 fractional works · 42.3% of its workGenetics: 2 fractional works · 1.8% of its workCancer Research: 1 fractional works · 1.3% of its workCell Biology: 1 fractional works · 0.6% of its workBiochemistry: 0 fractional works · 0.4% of its workBiotechnology: 0 fractional works · 0.4% of its workPhysiology: 0 fractional works · 0.3% of its workImmunology and Microbiology: 6 fractional works · 6.7% of its workImmunology: 6 fractional works · 6.6% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNeuroscience: 2 fractional works · 2.8% of its workEndocrine and Autonomic Systems: 2 fractional works · 2.1% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 1.4% of its workPharmaceutical Science: 1 fractional works · 0.9% of its workPharmacology: 0 fractional works · 0.5% of its workAgricultural and Biological Sciences: 0 fractional works · 0.5% of its workPlant Science: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workHealth Sciences: 28 fractional works · 33.3% of its workMedicine: 27 fractional works · 32.1% of its workOncology: 8 fractional works · 9.4% of its workHematology: 3 fractional works · 3.1% of its workRadiology, Nuclear Medicine and Imaging: 3 fractional works · 3.0% of its workGenetics: 2 fractional works · 2.5% of its workPulmonary and Respiratory Medicine: 2 fractional works · 2.2% of its workPhysiology: 1 fractional works · 1.7% of its workHepatology: 1 fractional works · 1.5% of its workOphthalmology: 1 fractional works · 1.1% of its workNephrology: 1 fractional works · 0.8% of its workEpidemiology: 1 fractional works · 0.7% of its workPsychiatry and Mental health: 1 fractional works · 0.7% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 0.7% of its workPathology and Forensic Medicine: 1 fractional works · 0.6% of its workRheumatology: 0 fractional works · 0.5% of its workSurgery: 0 fractional works · 0.5% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.3% of its workPharmacology: 0 fractional works · 0.3% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.3% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.3% of its workImmunology and Allergy: 0 fractional works · 0.3% of its workInfectious Diseases: 0 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 1.0% of its workNursing: 1 fractional works · 1.2% of its workNutrition and Dietetics: 1 fractional works · 1.2% of its workPhysical Sciences: 7 fractional works · 7.9% of its workEngineering: 2 fractional works · 2.9% of its workBiomedical Engineering: 2 fractional works · 2.3% of its workElectrical and Electronic Engineering: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workChemistry: 2 fractional works · 2.1% of its workOrganic Chemistry: 1 fractional works · 1.7% of its workSpectroscopy: 0 fractional works · 0.4% of its workMaterials Science: 1 fractional works · 1.5% of its workMaterials Chemistry: 1 fractional works · 1.1% of its workBiomaterials: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEnvironmental Science: 1 fractional works · 0.8% of its workEcology: 0 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPhysics and Astronomy: 0 fractional works · 0.5% of its workChemical Engineering: 0 fractional works · 0.1% of its workSocial Sciences: 0 fractional works · 0.4% of its workPsychology: 0 fractional works · 0.4% of its workSocial Psychology: 0 fractional works · 0.4% of its workALL ITS WORKNoxxon Pharma(Germany)84fractional works, all years
Life Sciences58%Physical Sciences8%Health Sciences33%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 14 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology4047.0%
    2. Immunology and Microbiology66.7%
    3. Neuroscience22.8%
    4. Pharmacology, Toxicology and Pharmaceutics11.4%
    5. Agricultural and Biological Sciences00.5%
    1. Medicine2732.1%
    2. Nursing11.2%
    1. Engineering22.9%
    2. Chemistry22.1%
    3. Materials Science11.5%
    4. Environmental Science10.8%
    5. Physics and Astronomy00.5%
    6. Chemical Engineering00.1%
    1. Psychology00.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What does Noxxon Pharma (Germany) specialise in?

Where its research is concentrated relative to its size: Molecular Biology takes 10.6× the share of its output that it takes of world research.

  1. Molecular BiologySubfield · 35.6 works11×
  2. Biochemistry, Genetics and Molecular BiologyField · 39.6 works6.8×
← less than its size predicts1×more →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Noxxon Pharma (Germany)?

Ranked on the quality score, Dirk Eulberg, Sven Klußmann and Dirk Zboralski lead among researchers whose main affiliation is Noxxon Pharma (Germany).

  1. 1 Dirk Eulberg Germany · #143,935 worldwide 4.8k citations · 64 works
  2. 2 Sven Klußmann Germany · #268,489 worldwide 6.2k citations · 107 works
  3. 3 Dirk Zboralski Germany · #472,577 worldwide 1.8k citations · 29 works
  4. 4 Axel Vater Germany · #484,691 worldwide 2.8k citations · 68 works
  5. 5 Christian Maasch Germany · #573,698 worldwide 2.5k citations · 40 works
  6. 6 Kai Hoehlig Germany · #590,136 worldwide 2.5k citations · 27 works
  7. 7 Anna Kruschinski Germany · #1,195,484 worldwide 1.1k citations · 44 works
  8. 8 Simone Sell Germany · #1,340,365 worldwide 1.3k citations · 17 works
  9. 9 Ingo Roehl Germany · #1,404,169 worldwide 907 citations · 19 works
  10. 10 Werner G. Purschke Germany · #1,518,977 worldwide 1.3k citations · 31 works
All ranked researchers at Noxxon Pharma (Germany)

What are the most cited papers from Noxxon Pharma (Germany)?

The most cited paper from Noxxon Pharma (Germany) is "Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury" (Christer Baeck, Alexander Wehr, Karlin Raja Karlmark et al., 2011), with 618 citations. Next come "Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension" (413) and "Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury" (327).

Most cited papers
#PaperReleasedCitations
1 Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury Christer Baeck, Alexander Wehr, Karlin Raja Karlmark et al. · Gut 3 Aug 2011 618
2 Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension Rajkumar Savai, Soni Savai Pullamsetti, Julia Kolbe et al. · American Journal of Respiratory and Critical Care Medicine 7 Sep 2012 413
3 Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury Jana C. Mossanen, Oliver Krenkel, Can Ergen et al. · Hepatology Open access 15 Jun 2016 327
4 Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice Christer Baeck, Xiao Wei, Matthias Bartneck et al. · Hepatology Open access 30 Jan 2014 276
5 CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis Josef Ehling, Matthias Bartneck, Xiao Wei et al. · Gut Open access 21 Feb 2014 275
All 60 most cited papers, with filters and sorting

Which keywords describe research at Noxxon Pharma (Germany)?

By fractional works in all years, weighted toward what it does more of than the world: Therapeutic Targets, Nanoparticles, Biosensors, Self-Assembly, aptamers, DNA nanotechnology, Nucleic Acids and DNA Structure.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Therapeutic Targets12▲ 59×4 topics
  2. Nanoparticles10▲ 8.7×6 topics
  3. Biosensors9▲ 18×3 topics
  4. Self-Assembly9▲ 26×4 topics
  5. DNA nanotechnology8▲ 96×1 topic
  6. aptamers8▲ 96×1 topic
  7. Inflammation8▲ 4.1×21 topics
  8. Nucleic Acids7▲ 108×2 topics
  9. DNA Structure7▲ 127×1 topic
  10. G-Quadruplexes7▲ 127×1 topic
  11. Translation6▲ 36×2 topics
  12. RNA Structure6▲ 73×1 topic
  13. Ribosome6▲ 73×1 topic
  14. Angiogenesis4▲ 13×6 topics
  15. Gene Therapy4▲ 19×3 topics
  16. Cell Migration4▲ 58×2 topics
  17. Cancer4▲ 3.4×13 topics
  18. Innate Immunity4▲ 13×8 topics
  19. Cancer Metastasis4▲ 137×2 topics
  20. Host Defense4▲ 67×2 topics
  21. Tumor Microenvironment4▲ 13×6 topics
  22. Chemokine Receptors4▲ 269×1 topic
  23. Chemokines4▲ 269×1 topic
  24. RNA Interference4▲ 37×1 topic
  25. siRNA Delivery4▲ 55×1 topic
  26. Drug Discovery3▲ 8.9×4 topics
  27. Immune Checkpoint Blockade2▲ 52×1 topic
  28. PD-1 and PD-L12▲ 52×1 topic
  29. Immunity2▲ 7.8×3 topics
  30. Glycosylation2▲ 11×2 topics
  31. Prognostic Factors2▲ 4.8×2 topics
  32. Hormonal Regulation2▲ 39×2 topics
  33. Ghrelin2▲ 60×1 topic
  34. Leptin2▲ 60×1 topic
  35. Cancer Immunotherapy2▲ 13×1 topic
  36. Dendritic Cells2▲ 16×1 topic
  37. PET Imaging2▲ 8.6×4 topics
  38. Rituximab2▲ 12×4 topics
  39. Gene Regulation1▲ 11×3 topics
  40. Targeted Therapy1▲ 7.7×3 topics

Which research topics does Noxxon Pharma (Germany) publish most on?

By volume in 2022-now: Graphene and Nanomaterials Applications, Graphene research and applications, Frailty in Older Adults and Childhood Cancer Survivors' Quality of Life.

Graphene and Nanomateria…0Graphene and Nanomaterials Applications: 0 fractional worksGraphene research and ap…0Graphene research and applications: 0 fractional worksFrailty in Older Adults0Frailty in Older Adults: 0 fractional worksChildhood Cancer Survivo…0Childhood Cancer Survivors' Quality of Life: 0 fractional worksPalliative Care and End-…0Palliative Care and End-of-Life Issues: 0 fractional worksNanowire Synthesis and A…0Nanowire Synthesis and Applications: 0 fractional worksAdvanced biosensing and …0Advanced biosensing and bioanalysis techniques: 0 fractional works
Biomedical EngineeringMaterials ChemistryGeriatrics and GerontologyPediatrics, Perinatology and Child Health2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Graphene and Nanomaterials Applications Biomedical Engineering 0 works
  2. 2 Graphene research and applications Materials Chemistry 0 works
  3. 3 Frailty in Older Adults Geriatrics and Gerontology 0 works
  4. 4 Childhood Cancer Survivors' Quality of Life Pediatrics, Perinatology and Child Health 0 works
  5. 5 Palliative Care and End-of-Life Issues Public Health, Environmental and Occupational Health 0 works
  6. 6 Nanowire Synthesis and Applications Biomedical Engineering 0 works
  7. 7 Advanced biosensing and bioanalysis techniques Molecular Biology 0 works
  8. 8 DNA and Nucleic Acid Chemistry Molecular Biology 0 works
  9. 9 Surface Chemistry and Catalysis Biomedical Engineering 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available43.0%not open57.0%

World: 40% of research is openly available.

with international co-authors34.4%domestic only65.6%

World: 18% is written across borders.

How has Noxxon Pharma (Germany)'s research output changed?

Output in 2022-2025 was 91% lower than in 2018-2021.

20002005201020152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Noxxon Pharma (Germany) as a percentage of every work published that year, 0.0000027% in 2022.

0.00025%0.00050%0.00075%Noxxon Pharma (Germany)0.0000090% in 2024200020102020

Fractional works of Noxxon Pharma (Germany) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Berlin

All research institutions in Berlin

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Noxxon Pharma (Germany). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.